Method comparison between hematopoietic progenitor cell and CD34+ cell counts in hematopoietic stem cell collection.

IF 2.5 3区医学 Q2 HEMATOLOGY

Transfusion Pub Date : 2024-09-01 Epub Date: 2024-07-05 DOI:10.1111/trf.17937

Thibault Lavalleye, Pascale Saussoy, Catherine Lambert

{"title":"Method comparison between hematopoietic progenitor cell and CD34+ cell counts in hematopoietic stem cell collection.","authors":"Thibault Lavalleye, Pascale Saussoy, Catherine Lambert","doi":"10.1111/trf.17937","DOIUrl":null,"url":null,"abstract":"Background: The reference method for hematopoietic stem cell enumeration is flow cytometric CD34+ cell analysis. We evaluated using the hematopoietic progenitor cell (HPC) count on the Sysmex hematology analyzer to safely replace some flow cytometric measurements performed in peripheral blood samples to guide apheresis timing.Study design and methods: We compared HPC and CD34+ cell counts in 133 preharvest peripheral blood samples and 124 apheresis products.Results: Pre-apheresis HPC counts ≥24 × 106/L in healthy donors and ≥36 × 106/L in lymphoma patients predicted adequate mobilization with 100% specificity and positive predictive value, saving 79% and 63% of flow cytometry analyses, respectively. Due to a positive bias (mean bias 50.26; 95% CI 36.24-64.29), a higher threshold was needed in multiple myeloma patients (HPC <math><mrow><mo>≥</mo></mrow> </math> 132 × 106/L), saving only 24% of flow cytometry analyses.Conclusion: When the HPC count is above the corresponding threshold, apheresis could be safely initiated without waiting for the flow cytometry result, thereby reducing time-to-decision. Lower HPC values, however, require confirmation by flow cytometry.","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/trf.17937","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The reference method for hematopoietic stem cell enumeration is flow cytometric CD34+ cell analysis. We evaluated using the hematopoietic progenitor cell (HPC) count on the Sysmex hematology analyzer to safely replace some flow cytometric measurements performed in peripheral blood samples to guide apheresis timing.

Study design and methods: We compared HPC and CD34+ cell counts in 133 preharvest peripheral blood samples and 124 apheresis products.

Results: Pre-apheresis HPC counts ≥24 × 10⁶/L in healthy donors and ≥36 × 10⁶/L in lymphoma patients predicted adequate mobilization with 100% specificity and positive predictive value, saving 79% and 63% of flow cytometry analyses, respectively. Due to a positive bias (mean bias 50.26; 95% CI 36.24-64.29), a higher threshold was needed in multiple myeloma patients (HPC $\geq$ 132 × 10⁶/L), saving only 24% of flow cytometry analyses.

Conclusion: When the HPC count is above the corresponding threshold, apheresis could be safely initiated without waiting for the flow cytometry result, thereby reducing time-to-decision. Lower HPC values, however, require confirmation by flow cytometry.

查看原文本刊更多论文

造血干细胞采集中造血祖细胞和 CD34+ 细胞计数的方法比较。

背景：造血干细胞计数的参考方法是流式细胞CD34+细胞分析。我们评估了使用 Sysmex 血液分析仪上的造血祖细胞（HPC）计数是否能安全地取代外周血样本中的某些流式细胞术测量，以指导血液净化时机的选择：研究设计：我们比较了133份采血前外周血样本和124份血液净化产品中的HPC和CD34+细胞计数：结果：健康献血者采血前HPC计数≥24 × 106/L和淋巴瘤患者采血前HPC计数≥36 × 106/L可预测充分的动员，特异性和阳性预测值均为100%，分别节省了79%和63%的流式细胞术分析。由于阳性偏倚（平均偏倚50.26；95% CI 36.24-64.29），多发性骨髓瘤患者需要更高的阈值（HPC ≥ $\ge $ 132 × 106/L），这仅节省了24%的流式细胞术分析：结论：当HPC计数高于相应的阈值时，可以安全地启动无细胞疗法，而无需等待流式细胞术结果，从而缩短了做出决定的时间。然而，较低的 HPC 值则需要通过流式细胞术进行确认。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion 医学-血液学

CiteScore

4.70

自引率

20.70%

发文量

426

审稿时长

1 months

期刊介绍： TRANSFUSION is the foremost publication in the world for new information regarding transfusion medicine. Written by and for members of AABB and other health-care workers, TRANSFUSION reports on the latest technical advances, discusses opposing viewpoints regarding controversial issues, and presents key conference proceedings. In addition to blood banking and transfusion medicine topics, TRANSFUSION presents submissions concerning patient blood management, tissue transplantation and hematopoietic, cellular, and gene therapies.